


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-16 (Canceled)

17. (Currently amended) A method of treatment of bacterial infections in mammals, particularly in man, which method comprises the administration to a mammal in need of such treatment of an effective amount of a quinoline of formula (I) or a pharmaceutically acceptable derivative thereof:



(I)

wherein:

m is 1 or 2;

each R¹ is independently hydroxy; (C₁₋₆) alkoxy optionally substituted by (C₁₋₆)alkoxy, amino, piperidyl, guanidino or amidino optionally N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl groups, NH₂CO, hydroxy, thiol, (C₁₋₆)alkylthio, heterocyclthio, heterocycloxy, arylthio, aryloxy, acylthio, acyloxy or (C₁₋₆)alkylsulphonyloxy; (C₁₋₆)alkoxy-substituted (C₁₋₆)alkyl; halogen; (C₁₋₆)alkyl; (C₁₋₆)alkylthio; nitro; azido; acyl; acyloxy; acylthio; (C₁₋₆)alkylsulphonyl; (C₁₋₆)alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl groups;

either R² is hydrogen; and

R³ is in the 2- or 3-position and is hydrogen or (C₁₋₆)alkyl or (C₂₋₆)alkenyl optionally substituted with 1 to 3 groups selected from:

thiol; halogen; (C₁₋₆)alkylthio; trifluoromethyl; azido; (C₁₋₆)alkoxycarbonyl; (C₁₋₆)alkylcarbonyl; (C₂₋₆)alkenyloxycarbonyl; (C₂₋₆)alkenylcarbonyl; hydroxy optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylcarbonyl or (C₂₋₆)alkenylcarbonyl; amino optionally mono- or disubstituted by (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, (C₂₋₆)alkenylsulphonyl or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl or (C₂₋₆)alkenyl; oxo; (C₁₋₆)alkylsulphonyl; (C₂₋₆)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; or

R³ is in the 3-position and R² and R³ together are a divalent residue =CR⁵¹R⁶¹ where R⁵¹ and R⁶¹ are independently selected from H, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, aryl(C₁₋₆)alkyl and aryl(C₂₋₆)alkenyl, any alkyl or alkenyl moiety being optionally substituted by 1 to 3 groups selected from those listed above for substituents on R³;

R⁴ is a group -CH₂-R⁵ in which R⁵ is selected from:

(C₃₋₁₂)alkyl; hydroxy(C₃₋₁₂)alkyl; (C₁₋₁₂)alkoxy(C₃₋₁₂)alkyl; (C₁₋₁₂)alkanoyloxy(C₃₋₁₂)alkyl; (C₃₋₆)cycloalkyl(C₃₋₁₂)alkyl; hydroxy-, (C₁₋₁₂)alkoxy- or (C₁₋₁₂)alkanoyloxy-(C₃₋₆)cycloalkyl(C₃₋₁₂)alkyl; cyano(C₃₋₁₂)alkyl; (C₂₋₁₂)alkenyl; (C₂₋₁₂)alkynyl; tetrahydrofuryl; mono- or di-(C₁₋₁₂)alkylamino(C₃₋₁₂)alkyl; acylamino(C₃₋₁₂)alkyl; (C₁₋₁₂)alkyl- or acyl-aminocarbonyl(C₃₋₁₂)alkyl; mono- or di-(C₁₋₁₂)alkylamino(hydroxy) (C₃₋₁₂)alkyl; optionally substituted phenyl(C₁₋₂)alkyl, phenoxy(C₁₋₂)alkyl or phenyl(hydroxy)(C₁₋₂)alkyl; optionally substituted diphenyl(C₁₋₂)alkyl; optionally substituted phenyl(C₂₋₃)alkenyl; optionally

substituted benzoyl or benzoylmethyl; optionally substituted heteroaryl(C₁-
2)alkyl; and optionally substituted heteroaroyl or heteroaroylmethyl;

or R⁴ is 3-benzoylpropyl or 3-(4-fluorobenzoyl)propyl;

n is 0, 1 or 2;

~~A is NR¹¹, O, S(O)_x or CR⁶R⁷ and B is NR¹¹, O, S(O)_x or CR⁸R⁹ where x is~~

~~0, 1 or 2 and wherein A is CR⁶R⁷ and B is CR⁸R⁹ and wherein:~~

~~each of R⁶ and R⁷, R⁸ and R⁹ R⁶, R⁷, R⁸ and R⁹ is independently selected
from: H; thiol; (C₁₋₆)alkylthio; halo; trifluoromethyl; azido; (C₁₋₆)alkyl; (C₂₋₆)alkenyl;
(C₁₋₆)alkoxycarbonyl; (C₁₋₆)alkylcarbonyl; (C₂₋₆)alkenyloxycarbonyl; (C₂₋
6)alkenylcarbonyl; hydroxy, amino or aminocarbonyl optionally substituted as for
corresponding substituents in R³; (C₁₋₆)alkylsulphonyl; (C₂₋₆)alkenylsulphonyl; or
(C₁₋₆)aminosulphonyl wherein the amino group is optionally substituted by (C₁₋
6)alkyl or (C₁₋₆)alkenyl;~~

~~or R⁶ and R⁸ together represent a bond and R⁷ and R⁹ are as above
defined;~~

~~or R⁶ and R⁸ together represent -O- and R⁷ and R⁹ are both hydrogen;~~

~~or R⁶ and R⁷ or R⁸ and R⁹ together represent oxo;~~

~~and each R¹¹ is independently H, trifluoromethyl, (C₁₋₆)alkyl, (C₁₋₆)alkenyl,
(C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, aminocarbonyl wherein the amino group
is optionally substituted by (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₁₋
6)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl, (C₁₋₆)alkyl or (C₁₋₆)alkenyl and
optionally further substituted by (C₁₋₆)alkyl or (C₁₋₆)alkenyl;~~

~~provided that A and B cannot both be selected from NR¹¹, O and S(O)_x and
when one of A and B is CO the other is not CO, O or S(O)_x~~

~~; wherein:~~

'heterocyclic' as used herein is an aromatic or non-aromatic, single or fused,
ring containing up to four hetero-atoms in each ring selected from oxygen, nitrogen
and sulphur, and having from 4 to 7 ring atoms which rings may be unsubstituted or
substituted by up to three groups selected from amino, halogen, (C₁₋₆)alkyl, (C₁₋
6)alkoxy, halo(C₁₋₆)alkyl, hydroxy, carboxy, carboxy salts, (C₁₋₆)alkoxycarbonyl,
(C₁₋₆)alkoxycarbonyl(C₁₋₆)alkyl, aryl, and oxo groups, and wherein any amino group

forming part of a single or fused non-aromatic heterocyclic ring as defined is optionally substituted by (C₁₋₆)alkyl optionally substituted by hydroxy, (C₁₋₆)alkoxy, thiol, (C₁₋₆)alkylthio, halo, trifluoromethyl, acyl or (C₁₋₆)alkylsulphonyl;


'heteroaryl' is an aromatic heterocyclic group referred to above;

'aryl' is phenyl or naphthyl, each optionally substituted with up to five groups selected from halogen, mercapto, (C₁₋₆)alkyl, phenyl, (C₁₋₆)alkoxy, hydroxy, (C₁₋₆)alkyl, mercapto (C₁₋₆)alkyl, halo(C₁₋₆)alkyl, hydroxy, amino, nitro, carboxy, (C₁₋₆)alkylcarbonyloxy, (C₁₋₆)alkoxycarbonyl, formyl, and (C₁₋₆)alkylcarbonyl groups; and

'acyl' is an (C₁₋₆)alkoxycarbonyl, formyl or (C₁₋₆)alkylcarbonyl group;

and wherein the pharmaceutically acceptable derivative is an acid addition salt, quaternary ammonium salt, or N-oxide.

18. (Currently amended) A compound of formula (IA) which is a compound of formula (I) wherein R³ is hydroxy(C₁₋₆)alkyl or 1,2-dihydroxy(C₂₋₆)alkyl optionally substituted on the hydroxy group(s) of formula (I) or a pharmaceutically acceptable derivative thereof:



wherein:

m is 1 or 2;

each R¹ is independently hydroxy; (C₁₋₆) alkoxy optionally substituted by (C₁₋₆)alkoxy, amino, piperidyl, guanidino or amidino optionally N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl groups, NH₂CO, hydroxy, thiol, (C₁₋₆)alkylthio, heterocyclylthio, heterocyclloxy, arylthio, aryloxy, acylthio, acyloxy or (C₁₋₆)alkylsulphonyloxy; (C₁₋₆)alkoxy-substituted (C₁₋₆)alkyl; halogen; (C₁₋₆)alkyl; (C₁₋₆)alkylthio; nitro; azido; acyl; acyloxy; acylthio; (C₁₋₆)alkylsulphonyl; (C₁₋₆)

6)alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋

6)alkylsulphonyl groups;

R² is hydrogen;

R³ is hydroxy(C₁₋₆)alkyl or 1,2-dihydroxy(C₂₋₆)alkyl optionally substituted on the hydroxy group(s);

R⁴ is a group -CH₂-R⁵ in which R⁵ is selected from:

(C₃₋₁₂)alkyl; hydroxy(C₃₋₁₂)alkyl; (C₁₋₁₂)alkoxy(C₃₋₁₂)alkyl; (C₁₋
12)alkanoyloxy(C₃₋₁₂)alkyl; (C₃₋₆)cycloalkyl(C₃₋₁₂)alkyl; hydroxy-, (C₁₋₁₂)alkoxy-
or (C₁₋₁₂)alkanoyloxy-(C₃₋₆)cycloalkyl(C₃₋₁₂)alkyl; cyano(C₃₋₁₂)alkyl; (C₂₋
12)alkenyl; (C₂₋₁₂)alkynyl; tetrahydrofuryl; mono- or di-(C₁₋₁₂)alkylamino(C₃₋
12)alkyl; acylamino(C₃₋₁₂)alkyl; (C₁₋₁₂)alkyl- or acyl-aminocarbonyl(C₃₋₁₂)alkyl;
mono- or di- (C₁₋₁₂)alkylamino(hydroxy) (C₃₋₁₂)alkyl; optionally substituted
phenyl(C₁₋₂)alkyl, phenoxy(C₁₋₂)alkyl or phenyl(hydroxy)(C₁₋₂)alkyl; optionally
substituted diphenyl(C₁₋₂)alkyl; optionally substituted phenyl(C₂₋₃)alkenyl; optionally
substituted benzoyl or benzoylmethyl; optionally substituted heteroaryl(C₁₋
2)alkyl; and optionally substituted heteroaroyl or heteroaroylmethyl;

or R⁴ is 3-benzoylpropyl or 3-(4-fluorobenzoyl)propyl;

n is 0, 1 or 2;

A is CR⁶R⁷ and B is CR⁸R⁹ and wherein:

R⁶, R⁷, R⁸ and R⁹ are independently selected from: H; thiol; (C₁₋₆)alkylthio;
halo; trifluoromethyl; azido; (C₁₋₆)alkyl; (C₂₋₆)alkenyl; (C₁₋₆)alkoxycarbonyl; (C₁₋
6)alkylcarbonyl; (C₂₋₆)alkenyloxycarbonyl; (C₂₋₆)alkenylcarbonyl; hydroxyl optionally
substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl,
(C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl or aminocarbonyl wherein the
amino group is optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋
6)alkylcarbonyl or (C₂₋₆)alkenylcarbonyl; amino optionally mono- or disubstituted by
(C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋
6)alkenylcarbonyl, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, (C₂₋
6)alkenylsulphonyl or aminocarbonyl wherein the amino group is optionally

substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxy carbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl or (C₂₋₆)alkenyl; (C₁₋₆)alkylsulphonyl; (C₂₋₆)alkenylsulphonyl; or (C₁₋₆)aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl or (C₁₋₆)alkenyl;

_____ or R⁶ and R⁸ together represent a bond and R⁷ and R⁹ are as above defined;


_____ or R⁶ and R⁸ together represent -O- and R⁷ and R⁹ are both hydrogen;

_____ or R⁶ and R⁷ or R⁸ and R⁹ together represent oxo;

_____ provided that when one of A and B is CO the other is not CO;

and wherein the pharmaceutically acceptable derivative is an acid addition salt, quaternary ammonium salt, or N-oxide.

19. (Currently amended) A compound of formula (IB) which is a compound of formula (I) wherein _____ at least one R¹ is (C₂₋₆) alkoxy substituted by optionally N-substituted amino, guanidino or amidino or C₁₋₆ alkoxy substituted by piperidyl, A is CH₂, CHOH, CH(NH₃), C(Me)(OH) or CH(Me) and B is CH₂, CHOH or CO of formula (I) or a pharmaceutically acceptable derivative thereof:



wherein:

_____ m is 1 or 2;

_____ at least one R¹ is (C₂₋₆) alkoxy substituted by optionally N-substituted amino, guanidino or amidino or (C₁₋₆) alkoxy substituted by piperidyl, and

each other R¹ is independently hydroxy; (C₁₋₆) alkoxy optionally substituted by (C₁₋₆)alkoxy, amino, piperidyl, guanidino or amidino optionally N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl groups, NH₂CO, hydroxy, thiol, (C₁₋₆)alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C₁₋

₆)alkylsulphonyloxy; (C₁₋₆)alkoxy-substituted (C₁₋₆)alkyl; halogen; (C₁₋₆)alkyl; (C₁₋₆)alkylthio; nitro; azido; acyl; acyloxy; acylthio; (C₁₋₆)alkylsulphonyl; (C₁₋₆)alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C₁₋₆)alkyl, acyl or (C₁₋₆)alkylsulphonyl groups;

either R² is hydrogen; and

R³ is in the 2- or 3-position and is hydrogen or (C₁₋₆)alkyl or (C₂₋₆)alkenyl optionally substituted with 1 to 3 groups selected from:

thiol; halogen; (C₁₋₆)alkylthio; trifluoromethyl; azido; (C₁₋₆)alkoxycarbonyl; (C₁₋₆)alkylcarbonyl; (C₂₋₆)alkenyloxycarbonyl; (C₂₋₆)alkenylcarbonyl; hydroxy optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylcarbonyl or (C₂₋₆)alkenylcarbonyl; amino optionally mono- or disubstituted by (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl, (C₂₋₆)alkenylcarbonyl, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkylsulphonyl, (C₂₋₆)alkenylsulphonyl or aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; aminocarbonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl, (C₂₋₆)alkenyl, (C₁₋₆)alkoxycarbonyl, (C₁₋₆)alkylcarbonyl, (C₂₋₆)alkenyloxycarbonyl or (C₂₋₆)alkenylcarbonyl and optionally further substituted by (C₁₋₆)alkyl, hydroxy(C₁₋₆)alkyl, aminocarbonyl(C₁₋₆)alkyl or (C₂₋₆)alkenyl; oxo; (C₁₋₆)alkylsulphonyl; (C₂₋₆)alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally substituted by (C₁₋₆)alkyl or (C₂₋₆)alkenyl; or

R³ is in the 3-position and R² and R³ together are a divalent residue =CR⁵¹R⁶¹ where R⁵¹ and R⁶¹ are independently selected from H, (C₁₋₆)alkyl, (C₂₋₆)alkenyl, aryl(C₁₋₆)alkyl and aryl(C₂₋₆)alkenyl, any alkyl or alkenyl moiety being optionally substituted by 1 to 3 groups selected from those listed above for substituents on R³;

R⁴ is a group -CH₂-R⁵ in which R⁵ is selected from:

(C₃₋₁₂)alkyl; hydroxy(C₃₋₁₂)alkyl; (C₁₋₁₂)alkoxy(C₃₋₁₂)alkyl; (C₁₋₁₂)alkanoyloxy(C₃₋₁₂)alkyl; (C₃₋₆)cycloalkyl(C₃₋₁₂)alkyl; hydroxy-, (C₁₋₁₂)alkoxy- or (C₁₋₁₂)alkanoyloxy-(C₃₋₆)cycloalkyl(C₃₋₁₂)alkyl; cyano(C₃₋₁₂)alkyl; (C₂₋₁₂)alkenyl; (C₂₋₁₂)alkynyl; tetrahydrofuryl; mono- or di-(C₁₋₁₂)alkylamino(C₃₋₁₂)alkyl; acylamino(C₃₋₁₂)alkyl; (C₁₋₁₂)alkyl- or acyl-aminocarbonyl(C₃₋₁₂)alkyl; mono- or di- (C₁₋₁₂)alkylamino(hydroxy) (C₃₋₁₂)alkyl; optionally substituted phenyl(C₁₋₂)alkyl, phenoxy(C₁₋₂)alkyl or phenyl(hydroxy)(C₁₋₂)alkyl; optionally substituted diphenyl(C₁₋₂)alkyl; optionally substituted phenyl(C₂₋₃)alkenyl; optionally substituted benzoyl or benzoylmethyl; optionally substituted heteroaryl(C₁₋₂)alkyl; and optionally substituted heteroaroyl or heteroaroylmethyl;

or R⁴ is 3-benzoylpropyl or 3-(4-fluorobenzoyl)propyl;

n is 0, 1 or 2;

A is CH₂, CHOH, CH(NH₂), C(Me)(OH) or CH(Me); and

B is CH₂, CHOH or CO;

and wherein the pharmaceutically acceptable derivative is an acid addition salt, quaternary ammonium salt, or N-oxide.

20. (Previously presented) A method according to claim 17 wherein R¹ is in the 6-position on the quinoline nucleus and is methoxy, amino(C₃₋₅)alkyloxy, nitro or fluoro and m is 1.

21. (Currently amended) A method according to claim 17 or 20 wherein R³ is (C₁₋₆) alkyl, (C₁₋₆) alkenyl, or optionally substituted 1-hydroxy-(C₁₋₆) alkyl.

22. (Currently amended) A method according to claim 21 wherein R³ is hydroxymethyl, 1- ~~hydroxyethyl~~ hydroxyethyl or 1,2-dihydroxyethyl wherein the 2-hydroxy group is optionally substituted with alkylcarbonyl or aminocarbonyl where the amino group is optionally substituted.

23. (Previously presented) A method according to claim 17 wherein R³ is in the 3-position.

24. (Currently amended) A method according to claim 17 wherein: A is ~~NH, NCH₃, O, CH₂, CHOH, CH(NH₃)~~ CH(NH₂), C(Me)(OH) or CH(Me) and B is ~~CH₂, CHOH, or CO or S_i~~ or A is CR⁶R⁷, and B CR⁸R⁹, and R⁶ and R⁸ together represent ~~-O-~~ and R⁷ and R⁹ are both hydrogen, and n is 0 or 1.

25. (Currently amended) A method according to claim 24 wherein:

~~A is NH, B is CO and n is 1 or 0;~~

~~A is O, B is CH₂ and n is 1 or 0;~~

A is CH₂ or CH₂OH, B is CH₂, and n is 1 or 0;

A is ~~NCH₃, CH(NH₃)~~ CH(NH₂), C(Me)(OH) or CH(Me), B is CH₂ and n is 1;

or

A is CR⁶R⁷, and B CR⁸R⁹, and R⁶ and R⁸ together represent ~~-O-~~ and R⁷ and R⁹ are both hydrogen, and n is 1.

26. (Previously presented) A method according to claim 17 wherein R⁴ is (C₅₋₁₀)alkyl, unsubstituted phenyl(C₂₋₃)alkyl or unsubstituted phenyl(C₃₋₄)alkenyl.

27. (Previously presented) A method according to claim 17 wherein R⁵ is unbranched at the α and, where appropriate, β positions.

28. (Currently amended) A compound of formula (I) as defined in claim 17 selected from:

[3R,4R]-3-Ethyl-1-hexyl-4-[3-oxo-3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R,4R]-3-Ethyl-1-hexyl-4-[3-(R,S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R,4R] 3-Ethyl-1-heptyl-4-[3-oxo-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-heptyl-4-[3-(R,S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
~~[3R,4R]-[3R,4R]-3-Ethyl-1-octyl-4-[3-oxo-3-(6-methoxyquinolin-4-yl)propyl]piperidine;~~
[3R,4R]-3-Ethyl-1-octyl-4-[3-(R,S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-decyl-4-[3-oxo-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-decyl-4-[3-(R,S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-dodecyl-4-[3-oxo-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R] 3-Ethyl-1-dodecyl-4-[3-(R,S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-cinnamyl-4-[3-(R,S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-heptyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethenyl-1-heptyl-4-[3-(R,S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-heptyl-4-[3-(R,S)-hydroxy-3-(6-hydroxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-1-Heptyl-3-(2-hydroxyethyl)-4-[3-(R,S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
~~[3R,4R] 3-Ethyl-1-heptyl-4-[3-(R,S)-hydroxy-3-(6-[5-phthalimidopentyloxy]-quinolin-4-yl)propyl]piperidine;~~
[3R,4R]-3-Ethyl-1-heptyl-4-[3-(R,S)-hydroxy-3-(6-[5-aminopentyloxy]-quinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-heptyl-4-[3-(R,S)-hydroxy-3-(6-[2-Amine- -amino-2-oxo-1,1-dimethyl]ethoxyquinolin-4-yl)propyl]piperidine;
~~[3R,4R] 3-Ethyl-1-heptyl-4-[3-(R,S)-hydroxy-3-(6-[2-hydroxy-2-methylpropionamido]quinolin-4-yl)propyl]piperidine;~~
[3R,4R]-3-Ethyl-1-heptyl-4-[3-(R,S)-hydroxy-3-(6-aminoquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-heptyl-4-[3-(R,S)-hydroxy-3-(6-azidoquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-heptyl-4-[3-(6-hydroxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-heptyl-4-[3-(6-propyloxyquinolin-4-yl)propyl]piperidine;

~~[3R,4R]-3-Ethyl-1-heptyl-4-[3-(6-(5-Phthalimidopentyloxy)-quinolin-4-yl)propyl]piperidine;~~
[3R,4R]-3-Ethyl-1-heptyl-4-[3-(6-(5-aminopentyloxy)-quinolin-4-yl)propyl]piperidine;
~~[3R,4R]-3-Ethenyl-1-(2-t-butyloxy-carbonylaminoethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;~~
[3R,4R]-3-Ethenyl-1-(2-phenoxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
~~[3R,4R]-3-Ethyl-1-(4-ethylbenzyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;~~
[3S,4R]-3-Ethenyl-1-heptyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethenyl-1-heptyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-1-Heptyl-3-(2-hydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-1-Heptyl-3-(2-acetoxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-1-Heptyl-3-(3-hydroxypropyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-1-Heptyl-3-(1-hydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-(2-phenylethyl)-4-[3-(R,S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-(3-phenylpropyl)-4-[3-(R,S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
Heptyl-4-[2-(R,S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
1-Heptyl-4-[3-(6-methoxyquinolin-4-yl)prop-2-enyl]piperidine;
1-Heptyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-heptyl-4-[3-(R,S)-hydroxy-3-(6-methoxyquinolin-4-yl)butyl]piperidine;
[3R,4R]-3-Ethenyl-1-heptyl-4-[3-(R,S)-azido-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethenyl-1-heptyl-4-[3-(R,S)-amino-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-heptyl-4-~~(3-(R,S)-4-[3-(R,S)-amino-3-(6-methoxyquinolin-4-yl)propyl]piperidine;~~
[3R,4R]-3-Ethyl-1-heptyl-4-[3-(6-methoxyquinolin-4-yl)butyl]piperidine;
[3R,4R]-3-Ethenyl-1-heptyl-4-~~(3-(R,S)-4-[3-(R,S)-acetamido-3-(6-methoxyquinolin-4-yl)propyl]piperidine;~~
[3R,4R]-1-Heptyl-3-(2-(R,S)-~~Hydroxypropyl~~-hydroxypropyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-1-Heptyl-3-(1-(R,S),2-dihydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R,4R]-1-Heptyl-3-aminocarbonyloxyethyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
~~[3R,4R]-3-Ethyl-1-heptyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;~~
[3R,4R]-3-(1-(R,S)-2-(1-(R,S)-2-Dihydroxyethyl)-1-heptyl-4-[3-(R,S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
~~[3R,4R]-3-Ethyl-1-heptyl-4-[(6-methoxyquinolin-4-yl)oxy)methyl]piperidine;~~
~~[3R,4S]-3-Ethenyl-1-heptyl-4-[2-(6-methoxyquinolin-4-yl)-oxyethyl]piperidine;~~
~~1-Heptyl-4-[(6-methoxyquinolin-4-yl)oxymethyl]piperidine;~~
~~[3R,4R]-3-Ethyl-1-heptyl-4-[(6-methoxyquinolin-4-yl)methylthiomethyl]piperidine;~~
~~[3R,4R]-1-Heptyl-3-ethenyl-4-[(6-methoxyquinoline-4-yl)carbonylamino)methyl]piperidine;~~
[3R,4R]-3-Ethenyl-1-heptyl-piperidine-4-[N-(6-methoxyquinolin-4-yl)]propionamide;
[3R,4R]-3-Ethenyl-1-heptyl-piperidine-4-[N-(6-methoxyquinolin-4-yl)]propylamine;
[3R,4S]-3-Ethenyl-1-heptyl-piperidine-4-[N-(6-methoxyquinolin-4-yl)]acetamide;
~~[3R,4R]-3-Ethenyl-1-heptyl-piperidine-4-[N-(6-methoxyquinolin-4-yl)]ethylamine;~~
[3R,4S]-3-Ethenyl-1-heptyl-4-[2-(R,S)-hydroxy-2-(6-methoxyquinolin-4-yl)ethyl]piperidine;
[3R,4R]-3-Ethenyl-1-heptyl-4-[2-(6-methoxyquinolin-4-yl)ethyl]piperidine;
[3R,4R]-3-Ethyl-1-heptyl-4-[2-(6-methoxyquinolin-4-yl)ethyl]piperidine;
1-Heptyl-4-[2(R,S)-hydroxy-2-(6-methoxy-4-quinolinyl)ethyl]-piperidine;
[3S,4R]-3-Ethenyl-1-heptyl-4-[2-(6-methoxyquinolin-4-yl)ethyl]piperidine;
N-(6-Methoxy-4-quinolinyl)-1-heptyl-4-piperidinecarboxamide;
(3Z)-(4R)-3-Ethylidene-1-heptyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
~~[3R,4S]-1-Cinnamyl-4-[2-(6-methoxyquinolin-4-yl)-oxyethyl]piperidine;~~
[3R,4R]-3-(2-Acetoxyethyl)-1-heptyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-heptyl-4-[3-(6-{2-hydroxyethyloxy}quinolin-4-yl)propyl]piperidine;
[3R,4R]-3-(Ethylaminocarbonyloxyethyl)-1-heptyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethenyl-1-heptyl-4-[3-(R,S)-aminocarbonylamino-3-(6-methoxyquinolin-4-yl)propyl]piperidine;
[3R,4R]-3-Ethyl-1-heptyl-4-[3-(6-(4-aminobutyloxy)-quinolin-4-yl)propyl]piperidine;
~~[3R,4R]-1-Heptyl-3-(1-(R)- and 1-(S)-hydroxy-2-methoxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;~~

[3R, 4R]-1-Heptyl-3-(1-(R)-hydroxy-2-methoxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R, 4R]-1-Heptyl-3-(1-(S)-hydroxy-2-methoxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R, 4R]-1-Heptyl-3-(1-(R)- and 1-(S)-hydroxy-2-methylthioethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R, 4R]-1-Heptyl-3-(1-(R)-hydroxy-2-methylthioethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R, 4R]-1-Heptyl-3-(1-(S)-hydroxy-2-methylthioethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R, 4R]-1-(5-Methylhexyl)-3-(1-(R)- and 1-(S)-2-dihydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R, 4R]-1-(5-Methylhexyl)-3-(1-(R),2-dihydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R, 4R]-1-(5-Methylhexyl)-3-(1-(S),2-dihydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R, 4R]-3-Ethyl-1-heptyl-4-[3-(6-(3-aminopropyl)oxyquinolin-4-yl)propyl]piperidine;

[3R, 4R]-3-Ethyl-1-heptyl-4-[3-(6-(2-aminoethyl)oxyquinolin-4-yl)propyl]piperidine;

[3R,4R]-3-Ethyl-1-heptyl-4-[3-(6-(3-guanidinopropyl)oxyquinolin-4-yl)propyl]piperidine;

[3R, 4R]-3-Ethyl-1-heptyl-4-[3-(6-(piperidine-4-yl)methoxyquinolin-4-yl)6-(piperidine-4-yl)methoxyquinolin-4-yl)propyl]piperidine;

[3R, 4S]-1-Heptyl-3-vinyl-4-[3-(6-methoxyquinolin-4-yl)-(R,R)-oxiran-2-ylmethyl]piperidine;

[3R, 4S]-1-Heptyl-4-[(2S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-3-vinylpiperidine;

[3R, 4S]-1-Heptyl-3-vinyl-4-[3-(6-methoxyquinolin-4-yl)-(S,S)-oxiran-2-ylmethyl]piperidine;

[3R, 4S]-3-Ethyl-1-heptyl-4-[2-(S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R, 4S]-1-Heptyl-4-[N-methyl-N-(6-methoxyquinolin-4-yl)aminoethyl]-3-vinylpiperidine;

[3R,4R]-1-Heptyl-3-(1-(R,S)-hydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R,4R]-1-Heptyl-3-(1-(R,S)-hydroxy-1-methylethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R,4R]-1-Heptyl-3-hydroxymethyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;

~~[3R,4R]-1-(6-Methylheptyl)-3-(1-(R) and 1-(S),2-dihydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;~~

[3R,4R]-1-(6-Methylheptyl)-3-(1-(R),2-dihydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R,4R]-1-(6-Methylheptyl)-3-(1-(S),2-dihydroxyethyl)-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine;

[3R, 4S]-1-Heptyl-4-[(2S)-hydroxy-3-(6-methoxyquinolin-4-yl)propyl]-3-(2-hydroxyethyl)piperidine; and


[3R, 4S]-1-Heptyl-3-aminocarbonyloxymethyl-4-[3-(6-methoxyquinolin-4-yl)propyl]piperidine; and

~~[3R, 4R]-1-Heptyl-4-[3-(6-methoxyquinolin-4-yl)propyl]-3-(2-carbamoylethyl)piperidine;~~


or a pharmaceutically acceptable acid addition salt, quaternary ammonium salt, or N-oxide derivative of any of the foregoing compounds.

29. (Withdrawn - currently amended) A process for preparing a compound of formula (IA)(I) or a pharmaceutically acceptable derivative thereof, according to claim 18 which process comprises:

(a) reacting a compound of formula (IV) with a compound of formula (V):



(IV)



(V)


wherein m, n, R¹, R², R³ and R⁴ are as defined in formula (I), and X and Y may be the following combinations:

- (i) X is M and Y is CH₂CO₂Rˣ
- (ii) X is CO₂Rʸ and Y is CH₂CO₂Rˣ
- (iii) one of X and Y is CH=SPh₂ and the other is CHO
- (iv) X is CH₃ and Y is CHO
- (v) X is CH₃ and Y is CO₂Rˣ

- (vi) X is $\text{CH}_2\text{CO}_2\text{R}^Y$ and Y is CO_2R^X
- (vii) X is $\text{CH}=\text{PR}^Z_3$ and Y is CHO
- (viii) X is CHO and Y is $\text{CH}=\text{PR}^Z_3$
- (ix) X is halogen and Y is $\text{CH}=\text{CH}_2$
- (x) one of X and Y is COW and the other is $\text{NHR}^{11'}$ or NCO
- (xi) one of X and Y is $(\text{CH}_2)_p\text{-V}$ and the other is $(\text{CH}_2)_q\text{NHR}^{11'}$, $(\text{CH}_2)_q\text{OH}$, $(\text{CH}_2)_q\text{SH}$ or $(\text{CH}_2)_q\text{SCOR}^X$ where $p+q=1$
- (xii) one of X and Y is CHO and the other is $\text{NHR}^{11'}$
- (xiii) one of X and Y is OH and the other is $-\text{CH}=\text{N}_2$


in which V and W are leaving groups, R^X and R^Y are (C_{1-6}) alkyl and R^Z is aryl or (C_{1-6}) alkyl;

(b) rearranging a compound of formula (II):




to give a compound of formula (III) which is a compound of formula (I) where R^3 is in the 3-position, n is 1, A-B is COCH_2 or disubstituted epoxide and R^2 is H, and thereafter optionally reducing to a compound of formula (VII) which is a compound of formula (I) where n is 1, A-B is CHOHCH_2 or CH_2CHOH and R^2 is H;

(c) photooxygenating a compound of formula (VI):




or

(d) reacting a compound of formula (IV) with a compound of formula (Vb):



(IV)




(Vb)


wherein m, n, R¹, R², R³ and R⁴ are as defined in formula (I), X is CH₂NHR^{11'} and Y is CHO or CO₂H or X is CH₂OH and Y is -CH=N₂; in which R^{11'}, R^{1'}, R^{2'}, R^{3'} and R^{4'} are R¹¹, R¹, R², R³ and R⁴ or groups convertible thereto, and thereafter optionally or as necessary converting R^{11'}, R^{1'}, R^{2'}, R^{3'} and R^{4'} to R¹¹, R¹, R², R³ and R⁴, converting A-B to other A-B, interconverting R¹¹, R¹, R², R³ and/or R⁴ and forming a pharmaceutically acceptable derivative thereof, wherein the pharmaceutically acceptable derivative is an acid addition salt, quaternary ammonium salt, or N-oxide.

30. (Withdrawn - currently amended) A process for preparing a compound of formula ~~(B)~~(I), or a pharmaceutically acceptable derivative thereof, according to claim 19 which process comprises:

(a) reacting a compound of formula (IV) with a compound of formula (V):



(IV)



(V)


wherein m, n, R¹, R², R³ and R⁴ are as defined in formula (I), and X and Y may be the following combinations:

- (i) X is M and Y is CH₂CO₂R^X
- (ii) X is CO₂R^Y and Y is CH₂CO₂R^X

- (iii) one of X and Y is $\text{CH}=\text{SPh}_2$ and the other is CHO
- (iv) X is CH_3 and Y is CHO
- (v) X is CH_3 and Y is CO_2R^X
- (vi) X is $\text{CH}_2\text{CO}_2\text{R}^Y$ and Y is CO_2R^X
- (vii) X is $\text{CH}=\text{PR}^Z_3$ and Y is CHO
- (viii) X is CHO and Y is $\text{CH}=\text{PR}^Z_3$
- (ix) X is halogen and Y is $\text{CH}=\text{CH}_2$
- (x) one of X and Y is COW and the other is $\text{NHR}^{11'}$ or NCO
- (xi) one of X and Y is $(\text{CH}_2)_p\text{-V}$ and the other is $(\text{CH}_2)_q\text{NHR}^{11'}$, $(\text{CH}_2)_q\text{OH}$, $(\text{CH}_2)_q\text{SH}$ or $(\text{CH}_2)_q\text{SCOR}^X$ where $p+q=1$
- (xii) one of X and Y is CHO and the other is $\text{NHR}^{11'}$
- (xiii) one of X and Y is OH and the other is $-\text{CH}=\text{N}_2$


in which V and W are leaving groups, R^X and R^Y are $(\text{C}_1\text{-}_6)$ alkyl and R^Z is aryl or $(\text{C}_1\text{-}_6)$ alkyl;

(b) rearranging a compound of formula (II):





to give a compound of formula (III) which is a compound of formula (I) where R^3 is in the 3-position, n is 1, A-B is COCH_2 or disubstituted epoxide and R^2 is H, and thereafter optionally reducing to a compound of formula (VII) which is a compound of formula (I) where n is 1, A-B is CHOHCH_2 or CH_2CHOH and R^2 is H;

(c) photooxygenating a compound of formula (VI):



or



(d) reacting a compound of formula (IV) with a compound of formula (Vb):



wherein m , n , R^1 , R^2 , R^3 and R^4 are as defined in formula (I), X is $CH_2NHR^{11'}$ and Y is CHO or CO_2H or X is CH_2OH and Y is $-CH=N_2$; in which $R^{11'}$, R^1 , R^2 , R^3 and R^4 are R^{11} , R^1 , R^2 , R^3 and R^4 or groups convertible thereto, and thereafter optionally or as necessary converting $R^{11'}$, R^1 , R^2 , R^3 and R^4 to R^{11} , R^1 , R^2 , R^3 and R^4 , converting A-B to other A-B, interconverting R^{11} , R^1 , R^2 , R^3 and/or R^4 and forming a pharmaceutically acceptable derivative thereof, wherein the pharmaceutically acceptable derivative is an acid addition salt, quaternary ammonium salt, or N-oxide.

31. (Withdrawn - currently amended) A process for preparing a compound of formula (I), or a pharmaceutically acceptable derivative thereof, according to claim 28 which process comprises:

(a) reacting a compound of formula (IV) with a compound of formula (V):




wherein m , n , R^1 , R^2 , R^3 and R^4 are as defined in formula (I), and X and Y may be the following combinations:

- (i) X is M and Y is $CH_2CO_2R^X$
- (ii) X is CO_2R^Y and Y is $CH_2CO_2R^X$
- (iii) one of X and Y is $CH=SPh_2$ and the other is CHO
- (iv) X is CH_3 and Y is CHO
- (v) X is CH_3 and Y is CO_2R^X
- (vi) X is $CH_2CO_2R^Y$ and Y is CO_2R^X
- (vii) X is $CH=PR^Z_3$ and Y is CHO
- (viii) X is CHO and Y is $CH=PR^Z_3$
- (ix) X is halogen and Y is $CH=CH_2$
- (x) one of X and Y is COW and the other is $NHR^{11'}$ or NCO
- (xi) one of X and Y is $(CH_2)_p-V$ and the other is $(CH_2)_qNHR^{11'}$, $(CH_2)_qOH$, $(CH_2)_qSH$ or $(CH_2)_qSCOR^X$ where $p+q=1$
- (xii) one of X and Y is CHO and the other is $NHR^{11'}$
- (xiii) one of X and Y is OH and the other is $-CH=N_2$


in which V and W are leaving groups, R^X and R^Y are (C_1-6) alkyl and R^Z is aryl or (C_1-6) alkyl;

(b) rearranging a compound of formula (II):





to give a compound of formula (III) which is a compound of formula (I) where R^3 is in the 3-position, n is 1, $A-B$ is $COCH_2$ or disubstituted epoxide and R^2 is H , and thereafter optionally reducing to a compound of formula (VII) which is a compound of formula (I) where n is 1, $A-B$ is $CHOHCH_2$ or CH_2CHOH and R^2 is H ;

(c) photooxygenating a compound of formula (VI):



or

(d) reacting a compound of formula (IV) with a compound of formula (Vb):



wherein m, n, R¹, R², R³ and R⁴ are as defined in formula (I), X is CH₂NHR^{11'} and Y is CHO or CO₂H or X is CH₂OH and Y is -CH=N₂;
in which R^{11'}, R^{1'}, R^{2'}, R^{3'} and R^{4'} are R¹¹, R¹, R², R³ and R⁴ or groups convertible thereto, and thereafter optionally or as necessary converting R^{11'}, R^{1'}, R^{2'}, R^{3'} and R^{4'} to R¹¹, R¹, R², R³ and R⁴, converting A-B to other A-B, interconverting R¹¹, R¹, R², R³ and/or R⁴ and forming a pharmaceutically acceptable derivative thereof, wherein the pharmaceutically acceptable derivative is an acid addition salt, quaternary ammonium salt, or N-oxide.

32. (Currently amended) A pharmaceutical composition comprising a compound or derivative according to claim 18, and a pharmaceutically acceptable carrier.

Serial No.: 09/600,984
Group Art Unit: 1626

33. (Currently amended) A pharmaceutical composition comprising a compound or derivative according to claim 19, and a pharmaceutically acceptable carrier.

Claim 34 (Canceled)